Literature DB >> 15834295

Angiotensin II and norepinephrine release: interaction and effects on the heart.

Markus P Schlaich1, David M Kaye, Elisabeth Lambert, Jacqui Hastings, Duncan J Campbell, Gavin Lambert, Murray D Esler.   

Abstract

BACKGROUND: Angiotensin (Ang) II may enhance the influence of the sympathetic nervous system at various levels by facilitating norepinephrine (NE) release. We investigated whether such an interaction is evident in the human heart and whether it has an impact on left ventricular (LV) structure. METHODS AND
RESULTS: Ang I and Ang II concentrations were determined in arterial and coronary sinus (CS) plasma samples in a group of normotensive (n = 10) and hypertensive (n = 18) subjects. Total systemic and cardiac NE spillover was measured using isotope dilution methodology and LV structure by echocardiography. Arterial and CS concentrations of Ang I and Ang II were similar in both groups (Ang II CS, 5.8 +/- 4.0 versus 3.7 +/- 3.1 fmol/ml; P = not significant), as was the Ang II/Ang I ratio (CS, 0.56 +/- 0.17 versus 0.54 +/- 0.22 fmol/fmol; P = not significant). Total systemic (223 +/- 145 versus 374 +/- 149 ng/min; P < 0.05) and cardiac NE spillover (11.7 +/- 6.3 versus 19.4 +/- 10.5 ng/min; P < 0.05) were increased in hypertensive patients, as was LV mass index (LVMI) (86.7 +/- 14.7 versus 117.2 +/- 19.4 g/m; P < 0.001). LVMI correlated with cardiac NE spillover (r = 0.47; P < 0.02). No correlation was evident between CS Ang II and cardiac NE spillover (r = 0.001; P = not significant) or LVMI (r = -0.20; P = not significant). Arterial Ang II tended to correlate with total systemic NE spillover (r = 0.34; P = 0.081). When hypertensive subjects were divided into two groups with either high or low CS Ang II concentration, cardiac NE spillover and LVMI did not differ between the two groups.
CONCLUSION: These findings suggest a growth-promoting effect of increased cardiac sympathetic tone on cardiomyocytes in hypertensive patients, but do not support the notion of a significant role of Ang II for norepinephrine release and LV hypertrophy in the hypertensive human heart.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834295     DOI: 10.1097/01.hjh.0000166850.80344.cf

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  10 in total

Review 1.  Premise, promise, and potential limitations of invasive devices to treat hypertension.

Authors:  Elizabeth A Martin; Ronald G Victor
Journal:  Curr Cardiol Rep       Date:  2011-02       Impact factor: 2.931

2.  Exercise-induced inhibition of angiotensin II vasoconstriction in human thigh muscle.

Authors:  R Matthew Brothers; Mads L Haslund; D Walter Wray; Peter B Raven; Mikael Sander
Journal:  J Physiol       Date:  2006-09-14       Impact factor: 5.182

Review 3.  Modulation of angiotensin II signaling following exercise training in heart failure.

Authors:  Irving H Zucker; Harold D Schultz; Kaushik P Patel; Hanjun Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-13       Impact factor: 4.733

4.  Protein kinase C (PKC) activity regulates functional effects of Kvβ1.3 subunit on KV1.5 channels: identification of a cardiac Kv1.5 channelosome.

Authors:  Miren David; Álvaro Macías; Cristina Moreno; Ángela Prieto; Ramón Martínez-Mármol; Rubén Vicente; Teresa González; Antonio Felipe; Michael M Tamkun; Carmen Valenzuela
Journal:  J Biol Chem       Date:  2012-04-30       Impact factor: 5.157

5.  Ca(2+) influx through L-type Ca(2+) channels and transient receptor potential channels activates pathological hypertrophy signaling.

Authors:  Hui Gao; Fang Wang; Wei Wang; Catherine A Makarewich; Hongyu Zhang; Hajime Kubo; Remus M Berretta; Larry A Barr; Jeffery D Molkentin; Steven R Houser
Journal:  J Mol Cell Cardiol       Date:  2012-08-21       Impact factor: 5.000

6.  PKC inhibition results in a Kv 1.5 + Kv β1.3 pharmacology closer to Kv 1.5 channels.

Authors:  A Macías; A de la Cruz; A Prieto; D A Peraza; M M Tamkun; T González; C Valenzuela
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 7.  Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.

Authors:  M Archer; N Dogra; Z Dovey; T Ganta; H-S Jang; J A Khusid; A Lantz; M Mihalopoulos; J A Stockert; A Zahalka; L Björnebo; S Gaglani; M R Noh; S A Kaplan; R Mehrazin; K K Badani; P Wiklund; K Tsao; D J Lundon; N Mohamed; F Lucien; B Padanilam; M Gupta; A K Tewari; N Kyprianou
Journal:  Cell Commun Signal       Date:  2021-07-20       Impact factor: 5.712

Review 8.  Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects.

Authors:  Oleg E Osadchii
Journal:  Heart Fail Rev       Date:  2007-03-27       Impact factor: 4.654

9.  Machine learning powered tools for automated analysis of muscle sympathetic nerve activity recordings.

Authors:  Janis M Nolde; Leslie Marisol Lugo-Gavidia; Revathy Carnagarin; Omar Azzam; Márcio Galindo Kiuchi; Ajmal Mian; Markus P Schlaich
Journal:  Physiol Rep       Date:  2021-08

10.  Arterial plasma vasopressin and aldosterone predict left ventricular mass in men who develop hypertension over 20 years.

Authors:  Arne H Strand; Helga Gudmundsdottir; Eigil Fossum; Ingrid Os; Reidar Bjørnerheim; Sverre E Kjeldsen
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-05       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.